TYME News and Press, Tyme Technologies Inc. From 05/27/21

4 Biotech Penny Stocks to Watch Right Now As you put together a penny stock watchlist for the month of June you might want to keep in mind what news could come out during the month. The biotech industry is well-known for releasing news often. This can occur prior to a new compounds roll...

4 Penny Stocks With Big Gains in 2021 As penny stock investors move into the latter half of the year, there’s no doubting that 2021 has been a wild ride. With the pandemic still in swing, cryptocurrency reaching new heights, and long-term fears of economic inflation abound, it&#x...

– Company to report conclusions from its comprehensive strategic review, outline its updated business plan and report its fiscal year 2021 financial results TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biote...

Best Penny Stocks to Buy Under $2? Check These 3 Out Penny stocks and the entire stock market are making big moves today. This comes only a day after a very disappointing trading session. And if it seems confusing, it’s worth noting that this is the normal trajectory that penny...

Gainers: Precipio (PRPO) +23%, PDS Biotechnology (PDSB) +20%, Sensei Biotherapeutics (SNSE) +18%, Iovance Biotherapeutics (IOVA) +17%, Tyme Technologies (TYME) +12%.Losers: Black Diamond Therapeutics (BDTX) -30%, Aerpio Pharmaceuticals (A...

Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...

TYME Technologies (TYME) announces that it has appointed Frank Porfido as the company's chief financial officer.Porfido is a biotech and pharmaceutical industry executive with over 25 years of strategic financial leadership expertise.Most recently, he served as the Vice President, F...

- Established executive with over 25 years of strategic financial leadership experience across small to large-size clinical and commercial-stage Pharma companies TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotech...

TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its abstract featuring data from the Company’s investigational therap...

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr. Van Tornout will prov...